Mangiferin Potentiates Neuroprotection by Isoflurane in Neonatal Hypoxic Brain Injury by Reducing Oxidative Stress and Activation of Phosphatidylinositol-3-Kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR) Signaling

Jia-shui Xi
Yu-fen Wang
Xin-xin Long
Yan Ma

Background: Hypoxic-ischemic brain injury in the perinatal period is a main cause of perinatal mortality and neurologic complications in neonates and children. Recent studies have focused on the neuroprotective effect of anesthetic drugs. The volatile anesthetic isoflurane has been shown to exert neuroprotective effects in cerebral ischemia. Mangiferin is a natural polyphenol with various pharmacological properties, including antioxidant and anti-tumor effects. This study aimed to determine whether mangiferin potentiates the neuroprotective effects of isoflurane and also if mangiferin when administered alone exerts neuroprotective effects following hypoxic-ischemic brain injury.

Material/Methods: Sprague-Dawley rats were subjected to cerebral hypoxic ischemia on postnatal day 10 (P10). Mangiferin (50, 100, or 200 mg/kg b.w.) was intragastrically administered from P3 to P12 and 1 h prior to insult on the day of ischemic induction. At 3 h after hypoxia-ischemia (HI) insult, separate groups of rat pups were exposed to isoflurane (1.5%) for 6 h. Following 48 h of HI, the rats were sacrificed and brain tissues were used for analysis.

Results: Mangiferin treatment attenuated neuronal apoptosis and reduced cerebral infarct volume. The expression of cleaved caspase-3 and apoptotic cascade proteins were regulated. The levels of reactive oxygen species (ROS) and malondialdehyde were reduced by mangiferin and/or isoflurane exposure. The levels of antioxidant glutathione were considerably raised under HI injury, which was modulated by mangiferin and isoflurane exposure. The PI3K/Akt signaling pathway, which was downregulated following HI insult, was activated by mangiferin and/or isoflurane.

Conclusions: This study reveals the potent neuroprotective efficacy of mangiferin against HI-induced brain injury via effectively modulating apoptotic pathways, ROS levels, and PI3K/Akt cascades while potentiating protective effects of isoflurane.

MeSH Keywords: Brain Injuries • Cell Hypoxia • Isoflurane • Phosphatidylinositol 3-Kinases

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/908142
Background

Perinatal hypoxia-ischemia (HI) has high global incidence of 1–8 per 1000 live births and is the main cause of mortality and neurological complications such as epilepsy, cerebral palsy, cognitive deficits, and visual and hearing impairments in neonates and children [1–6]. The pathophysiology of neonatal HI includes excitotoxicity, oxidative stress, neuroinflammation, and apoptosis [5,7].

Identification and development of effective neuroprotective compounds could be of immense clinical value. Recent studies have explored the neuroprotective effects of sevoflurane and isoflurane, which are commonly used volatile anesthetics. Isoflurane, administered prior to or after experimental cerebral ischemia has been found to exert neuroprotective effects in rodent models [8–12]. Neuroprotective effects of the inhalation anesthetic, sevoflurane, following cerebral ischemic injury has been reported to be mediated via activation of the PI3K/Akt (phosphoinositide 3-kinase/Protein kinase B) pathway [13,14].

The PI3K/Akt (phosphoinositide 3-kinase/Protein kinase B) signaling pathway regulates various processes, including cell growth, survival, and metabolism [15]. Wang et al. [16] demonstrated the neuroprotective role of the PI3K/Akt signaling pathway in an ischemic stroke model. This pathway is negatively regulated by phosphatase and tensin homolog (PTEN) [15]. Mammalian target of rapamycin (mTOR), one of the main downstream effectors of the pathway, exists as a multiprotein complex of mTORC1 and mTORC2 [15]. mTORC1, upon activation by Akt, subsequently leads to cell cycle progression. mTORC2 activates Akt in turn, providing a positive feedback loop aiding cell proliferation and survival [17]. Additionally, Akt can phosphorylate and deactivates glycogen synthase kinase 3β (GSK3β), a serine/threonine kinase, which leads to increased expressions of the cell cycle protein cyclin D1 [11]. Nuclear factor-κB (NF-κB), a central transcriptional factor, is also regulated and activated by Akt; it also activates the inhibitor of κB (IκB) kinase (IKK) and is activated by Akt. Upon activation, it causes phosphorylation and degradation of IκB, leading to subsequent release of NF-κB, which translocates to the nucleus and triggers transcription target genes. Akt is also documented to suppress apoptosis. The activation of PI3K/Akt signaling pathway leads to cell survival and to reduced cellular apoptosis [15].

It is well documented that oxidative stress, an imbalance between oxidant and antioxidant factors, is a chief contributor to ischemic brain injury [18,19]. Excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) is detrimental and causes damage to the biomolecules, ultimately leading to neuronal degeneration and death [20,21]. The developing neonatal brain is susceptible to oxidative stress and damage, due to immature radical scavenging systems, following injury [22]. Antioxidants counteract with free radicals and terminate the chain reaction [21]. Thus, it is rational to assume that exogenous antioxidant therapy could help reduce the associated cellular damage [23].

Recent studies have demonstrated the neuroprotective efficacy of plant-derived compounds in stroke and ischemic injury [7,24,25]. Mangiferin (C-glucopyranoside 1,3,6,7-tetrahydroxanthone) is a phytopolyphenol naturally present in numerous plant species such as Mangifera indica and Iris unguicularis [26]. Mangiferin exhibits various pharmacological properties such as antioxidant [27,28], anti-inflammatory [29], anti-tumor [30,31], and anti-diabetic effects [32]. Considering its wide array of bioactive properties, the present study explored the effects of mangiferin against experimental neonatal hypoxic brain injury.

Material and Methods

Experimental animals

The experimental design and protocols were approved by the Institutional Animal Ethics Committee of Provincial Hospital Affiliated to Shandong University. Pregnant Sprague-Dawley rats were housed in separate sterile plastic cages with 12 h light/12 h dark cycle at 25±1°C temperature and 50–60% humidity and were provided with water and standard pellet diet. The animals were carefully monitored for the birth of pups. The day of birth of pups was noted as postnatal day 0 (P0). On postnatal day 10 (P10) (weight, 22 to 30 g), the pups were subjected to hypoxic insult. All the experiments were carried out in compliance with the guidelines of the law of China for use of laboratory animals and also the National Institute of Health Guide for the Use of Laboratory Animals [33].

Antibodies and chemicals

Primary antibodies against Bcl-2, Bax, Bad, and Bcl-xL were procured from Abcam (USA). Akt, p-Akt, mTORC1, p-mTORC1, mTORC2, p-mTORC2, phosphatase and tensin homolog (PTEN), glycogen synthase kinase 3β (GSK-3β), p- GSK-3β (Ser9), NF-κBp65, and cleaved caspase-3 were procured from Cell Signaling Technology (Danvers, MA, USA). CyclinD1, β-actin, and horseradish- and peroxidase-labeled IgG secondary antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA) and used for expression analysis. Cell lysis buffer for Western blotting analysis was purchased from Beyotime Institute of Biotechnology (Beijing, China). Mangiferin and isoflurane were procured from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals used for analysis were obtained from Sigma-Aldrich.
Experimental design and dosing

The experimental animals were randomly separated to groups (n=12/group) as follows: Group 1 – Control – were not subjected to HI and received no isoflurane or mangiferin, Group 2 – HI control – animals were subjected to HI and did not receive isoflurane or mangiferin, Groups 3–5 – animals were subjected to HI and received mangiferin alone at (50, 100, or 200 mg/kg bodyweight); Group 6 – animals subjected to HI were exposed to isoflurane alone (1.5%); Groups 7–9 – animals received mangiferin (50, 100, or 200 mg/kg bodyweight) and exposed to isoflurane.

A separate group of rat pups (n=12 per group) were administered mangiferin (50, 100 or 200 mg/kg body weight) via oral gavage every day from P3 to P12, and on the day of HI, mangiferin was administered 1 h prior to insult. The doses of mangiferin were chosen based on the previous experiments conducted in our laboratory with varying doses of mangiferin (data not included). Cerebral HI was induced as previously described by Vannucci et al. [1] on P10 with slight variations. In brief, rats were anesthetized (3% halothane) and a 3-mm midline cervical incision was made and the left common carotid artery was isolated and ligated using 6-0 surgical silk at 2 locations. The common carotid artery was then transected between the ligatures to ensure that there was no blood flow through the ipsilateral carotid. The incision was sutured and the pups were placed in their respective cages and were allowed to recover for 2 h. The pups were then placed in a temperature-controlled chamber and subjected to 8% O₂ for 2 h at 37°C. At 3 h after insult, a separate group of pups were exposed to isoflurane (1.5% with air as carrier; gas flow 2 L/min) continuously for 6 h [1,34]. After 6 h of isoflurane exposure, the rats were removed from the chamber and exposed to air. The animals were observed for free movements and then placed back in their respective maternal cages.

On P12, the rats were killed by with transcardial perfusion of 10% formalin in PBS. The brains were excised immediately after sacrifice and the wet weight was measured. 2,3,5-triphenyltetrazoliumchloride (TTC) staining was performed to evaluate brain viability and to measure the infarct size. The brain tissues were sectioned (2-mm sections) and were incubated with TTC for 30 min (37°C). The tissue sections were then immersed in 4% paraformaldehyde in the dark overnight. The infarct area was determined using NIH Image J software (Version 1.42; National Institutes of Health, Bethesda, MD). Normal areas of the brain stain with TTC, while the infarct areas remain unstained. Infarct volume was calculated by adding the infarct area of every section x thickness of the sections. The results are presented as percentage infarction/ipsilateral hemisphere.

Determination of apoptosis by TUNEL analysis

Terminal transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed to assess apoptosis following hypoxic insult using the DeadEnd TM fluorometric TUNEL system kit (Promega, Madison, WI, USA) according to manufacturer’s protocol. In brief, 5-μm-thick paraffin-embedded brain tissue sections were subjected to analysis. The TUNEL-positive cells were visualized and analyzed by NIS-Elements BR imaging processing and analysis software (version 4.0, Nikon Corporation, Japan).

Immunohistochemistry

Neuroapoptosis was further assessed by detecting cleaved caspase-3 expression levels by immunohistochemistry (IHC) as described previously [35]. The brain sections (10-μm slices) were incubated with cleaved caspase-3 primary antibody (1: 1000, Cell Signaling Technology) overnight at 4°C. The tissue sections were then washed with PBS and blocked with 1.6% H₂O₂ in PBS for 10 min at room temperature. After washing with PBS, the sections were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (1: 500, Santa Cruz Biotechnology, Dallas, TX, USA) for 60 min at room temperature and then treated with diaminobenzidine. Cleaved caspase-3 positive cells were quantified and analyzed as described in TUNEL assay.

Assay of malondialdehyde and glutathione levels

Brain tissue (n=6) was homogenized with 1: 10 (w/v) PBS on ice and centrifuged (3000 rpm; 15 min, 4°C) and the supernatant was collected and used for assay of ROS and antioxidant levels. Concentration of the total protein in the supernatant was determined using the Bradford protein assay kit (Bio-Rad, Hercules, CA, USA). The concentrations of glutathione (GSH) and malondialdehyde (MDA) in the samples were determined.
using assay kits from Sigma-Aldrich, according to the manufacturer’s protocols.

**Determination of ROS**

The *in vitro* ROS/RNS assay kit (OxiSelect™) (Cat No – STA-342-5; Cell Bio Labs, Inc.) was used to determine ROS levels in the brain tissues. A fluorogenic probe dichlorodihydrofluorescein DiOxyQ (DCFH-DiOxyQ) that is specific to ROS/RNS and which is similar to 2′, 7′-dichlorodihydrofluorescein diacetate was used in the assay. DCFH-DiOxyQ is stabilized first to highly reactive DCFH that reacts with ROS and RNS and becomes oxidized to highly fluorescent DCF. The fluorescence intensity was measured (480 nm excitation and 530 nm emission) using the Synergy™ 2 Multi-function Microplate Reader.

**Western blot analysis**

The brain hemispheres (n=6) following HI were homogenized on ice using cell lysis buffer and were centrifuged at 15 000 rpm and 4°C for 10 min. Concentration of the total protein in the supernatant was determined using a bicinchoninic acid (BCA) protein assay kit (Bio-Rad, Hercules, CA, USA). Further, to assess NF-κB (p65) expression both in the cytosolic and nuclear fractions, an aliquot of the homogenate was separated into fractions using an NE-PER nuclear and cytoplasmic extraction reagents kit (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer’s instructions. Equal amounts (50 µg) of protein samples (for NF-κB, p65) from both the fractions/group from different experimental groups were electrophoretically separated on SDS-PAGE (2%) and electrotransferred on to polyvinylidene difluoride (PVDF) membranes (Invitrogen). Using 5% BSA (fetal bovine serum albumin) in Tris-buffered saline containing Tween-20, 0.1% (TBST), the membrane was blocked for 2 h at room temperature and then incubated overnight at 4°C with respective primary antibodies, after which, the blots were washed using TBST and further incubated for 2 h at room temperature with HRP-conjugated secondary antibodies. The immunoreactive bands were visualized and scanned using an Image Master II scanner (GE Healthcare, Milwaukee, WI, USA). The band densities were further analyzed by ImageQuant TL software (GE Healthcare, Milwaukee, WI, USA). The expression of the test proteins was standardized with that of β-actin.

**Statistical analysis**

The results are expressed as mean ± standard deviation calculated from 6 individual experiments. The statistical analysis was carried out using SPSS software (version 22.0, SPSS Inc., Chicago, IL, USA). Multiple group comparisons were analyzed using analysis of variance (ANOVA) followed by Duncan’s multiple range test (DMRT). A *p*-value <0.05 was considered significant.
The observations revealed the severe infarction following HI. The observations revealed the severe infarction. TTC staining was performed to assess the extent of infarction. Mangiferin and isoflurane reduced infarct area compared to control animals than in animals that were exposed to isoflurane. However, the infarct volume was markedly smaller in rats treated with mangiferin and exposed to isoflurane in comparison to rats that were treated with either mangiferin or exposed to isoflurane.

**Mangiferin and isoflurane reduce HI-induced apoptosis**

TUNEL assay was performed to explore the neuroprotective effects of mangiferin and isoflurane. The results indicated that treatment with mangiferin (50, 100, or 200 mg) significantly (p<0.05) inhibited ischemia-induced neuronal cell death (Figure 3A). Further, IHC analysis revealed significantly (p<0.05) reduced cleaved caspase-3 expression in rats that were treated with mangiferin (Figure 3B). Isoflurane post-treatment also resulted in substantial decrease in cleaved caspase-3-positive cells as compared to the HI control group. However, the cleaved caspase-3-positive cell counts were higher in animals treated with mangiferin or isoflurane alone as compared to rats that were treated with mangiferin and exposed to isoflurane.

Further, Western blot analysis revealed significantly (p<0.05) enhanced cleaved caspase-3 expression along with elevated (p<0.05) levels of pro-apoptotic proteins Bax and Bad at 48 h after HI injury (Figure 4). Bcl-2 and Bcl-xl expression was observed to be substantially inhibited, indicating activation of the apoptotic cascade. Interestingly, post-treatment with isoflurane and/or treatment with mangiferin downregulated cleaved caspase-3, Bax and Bad expression, while the levels of Bcl-xl and Bcl-2 were elevated. In line with TUNEL-positive counts, the results of protein expression also illustrated that mangiferin treatment and exposure to isoflurane offered significant neuroprotective effects compared to treatment with mangiferin or isoflurane. We observed 200-mg mangiferin to be more effective in comparison to lower doses, irrespective of whether administered alone or followed by isoflurane post-treatment on P10.

**Isoflurane and mangiferin decreased ROS levels following HI**

Oxidative stress as a major contributor to hypoxic-ischemic brain injury is well documented [7]. Our data show a significant (p<0.05) increase in ROS levels following HI (Figure 5A). Interestingly, isoflurane reduced ROS levels considerably as compared to the HI control group. However, the levels of ROS in the mangiferin-treated group were markedly (p<0.05) lower as compared to the isoflurane alone group. Further, isoflurane and mangiferin treatment resulted in lower ROS levels compared to mangiferin alone groups, illustrating the
antioxidant potential of mangiferin that could have potentiated the effects of isoflurane on neutralizing ROS levels. In line with the ROS levels, MDA content was markedly higher (p<0.05) in the HI control group compared to normal controls. Elevated GSH levels (Figure 5B, 5C) neutralized increased ROS. Interestingly, mangiferin treatment significantly (p<0.05) reduced MDA content, but no such effects were seen in the GSH levels. Isoflurane caused a marked decrease in GSH levels as opposed to the HI alone group. In the mangiferin and isoflurane groups, considerable increases in GSH levels were noticed. Further, the reduction in MDA levels was more pronounced in mangiferin treatment compared to isoflurane post-treatment. However, in rats exposed to mangiferin and isoflurane, MDA levels were significantly (p<0.05) reduced as compared to the isoflurane alone group.

Mangiferin and isoflurane activate the PI3K/Akt pathway

To further assess if the PI3K/Akt signaling pathway underlies mangiferin and isoflurane-induced neuroprotection in the neonatal HI model, we measured the expression of major effector proteins of the pathway. HI caused marked down-regulation in the levels of p-Akt, p-GSK-3β, p-mTORC1, and NF-κB p65, and significantly upregulated PTEN levels (Figure 6). Expression levels of cyclinD1 and p-IκBα were also reduced. However, the levels of phosphorylation of Akt, GSK-3β, mTORC1, and IκBα were significantly (p<0.05) increased, with suppressed PTEN expression after isoflurane post-treatment, suggesting activation of the pathway. Mangiferin treatment also significantly (p<0.05) increased phosphorylation of Akt, GSK-3β, mTORC1, and IκBα.
and IκBα in a dose-dependent manner. However, in animals treated with mangiferin and exposed to isoflurane, activation of the pathway was more marked as compared to isoflurane or mangiferin treatment.

**Discussion**

Hypoxic-ischemic brain injury is a major cause of neonatal death and neurologic sequelae in neonates and infants. Neonatal HI presents high morbidity rates and survivors live with long-term neurological impairments, such as epilepsy and cerebral palsy [36,37]. Several pathophysiological factors such as excitotoxicity, inflammatory mediators, and oxidative stress have been associated in hypoxia-ischemia [5]. The volatile anesthetic isoflurane has been demonstrated to exert protective effects against ischemic injury in various organs [38–40]. The present study explored whether mangiferin improved the effects of isoflurane in a neonatal HI model.

We found that isoflurane (1.5%) exposure immediately after HI significantly restored histology of hippocampal tissue and reduced infarct volume and number of TUNEL-positive cells. Further, mangiferin administration was found to reduce neuronal loss and infarct volume. These observations suggest that mangiferin augmented the neuroprotective effects of isoflurane. Further, immunohistochemical analysis revealed downregulated expression of cleaved caspase-3, a marker of apoptotic cell death. It is known that the balance between the pro-apoptotic proteins (Bad and Bax) and anti-apoptotic proteins (Bcl-2 and Bcl-xL) critically regulates cell survival [41]. The effect of up-regulated expression of Bcl-2 and Bcl-xL, along with downregulated Bad and Bax, on mangiferin and/or isoflurane treatment illustrates promotion of cell survival. Interestingly, exposure

**Figure 5.** Mangiferin and isoflurane reduced HI-induced ROS. (A) Values are mean ±SD, n=6, p<0.05 as determined by one-way ANOVA followed by DMRT analysis. * Represents p<0.05 vs. control; # represents p<0.05 vs. HI control; @ represents HI + Mangiferin (200 mg) + Isoflurane vs. HI + Isoflurane and Mangiferin (200 mg) + HI at p<0.05 vs. isoflurane. Different letters in different experimental groups indicate significant differences at p<0.05. (B) Mangiferin and isoflurane reduced HI-induced MDA levels. Values are mean ±SD, n=6, p<0.05 as determined by one-way ANOVA followed by DMRT analysis. * Represents p<0.05 vs. control; # represents p<0.05 vs. HI control; @ represents HI + Mangiferin (200 mg) + Isoflurane vs. HI + Isoflurane and Mangiferin (200 mg) + HI at p<0.05 vs. isoflurane. Different letters in different experimental groups indicate significant differences at p<0.05. (C) Mangiferin reduced HI-induced ROS, MDA levels and enhances GSH levels. Values are mean ±SD, n=6, p<0.05 as determined by one-way ANOVA followed by DMRT analysis. * Represents p<0.05 vs. control; # represents p<0.05 vs. HI control; @ represents HI + Mangiferin (200 mg) + Isoflurane vs. HI + Isoflurane and Mangiferin (200 mg) + HI at p<0.05 vs. isoflurane. Different letters in different experimental groups indicate significant differences at p<0.05.

**Figure 6.** Effect of mangiferin and propofol on expression of major effector proteins of the PI3K/Akt pathway – representative Western blot images. L1 – HI control; L2 – Mangiferin (100 mg/kg) + HI; L3 – Mangiferin (200 mg/kg) + HI; L4 – HI + Isoflurane (1.5%); L5 – Mangiferin (100 mg/kg) + HI + Isoflurane; L6 – Mangiferin (200 mg/kg) + HI + Isoflurane.
to both mangiferin and isoflurane was found to reduce apoptosis and improve cell survival, indicating that mangiferin potentiated neuroprotective effects of isoflurane.

Oxidative stress is well documented as a major contributor in the pathology of HI [42]. The neonatal brain is highly vulnerable to oxidative stress due to lack of adequate antioxidants to combat the excessive ROS, leading to neurotoxicity [42–45]. Elevated ROS levels and MDA levels in our study reflect oxidative stress following HI. Raised levels of the antioxidant GSH indicates cellular defence responses to stress. Mangiferin administration was found to attenuate the oxidative stress. Mangiferin reduced ROS production and MDA levels but mangiferin did not cause such effects on the GSH levels. This is probably due to the effective contribution of mangiferin in neutralization of ROS, which contributed to decreased oxidative stress levels. Reduced stress levels as observed in mangiferin treatment may have not induced GSH levels. Excessive ROS causes response from native antioxidant defence and the reduction in ROS levels by mangiferin reflects reduced oxidative stress condition. These results indicate the antioxidant potential of mangiferin.

Isoflurane exposure following HI insult slightly increased the antioxidant levels and reduced the ROS levels; nevertheless, the changes were significantly less than the effects of mangiferin. Further, isoflurane was observed to decrease GSH levels. Studies have reported that prolonged exposure to isoflurane reduces GSH levels [46,47]. The observed decrease could be attributed to the raised oxidative stress conditions on induction of HI injury and, in part, isoflurane could have contributed to decreased GSH levels, as reported in previous studies. This reduction in GSH reflects overutilization of the enzyme against ROS. Nevertheless, mangiferin and isoflurane administration enhanced GSH and reduced MDA and ROS levels, reflecting the capacity of mangiferin in aiding the potential of isoflurane as a neuroprotective agent. Increased GSH levels on administration of mangiferin and isoflurane vs. the isoflurane alone group suggest the efficacy of mangiferin in improving the antioxidant status, which in part could have aided in reduced ROS and MDA levels apart from direct neutralization of ROS by mangiferin, illustrating the effects of mangiferin in potentiating the effects of isoflurane. This reduction in ROS could have also aided in reduction in neuronal apoptosis. These effects could be attributed to the antioxidant capacity of mangiferin.

The phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway is expressed widely in the CNS during development; it mediates cell survival and differentiation and cellular metabolisms, which are involved in neurocyte nutrition [48–50]. GSΚ-3β, an important downstream protein of Akt, is reported to be involved in HI brain damage. GSΚ-3β experts pro-apoptotic effects in HI brain injury via activation of p53, thus making proteins of the PI3K/Akt/GSK-3β signaling pathway targets in treatment of HI [51–53]. Studies have reported that activation of the PI3K/Akt pathway increases neuroprotection and neuronal cell survival [54,55].

In the present study, HI-induced significant suppression of the pathway was observed to be markedly activated by isoflurane and/or mangiferin. mTORC2 causes phosphorylation and activation of Akt. Mangiferin and/or isoflurane mediated enhanced expression of mTORC2, and p-mTORC2 could have caused enhanced phosphorylated Akt levels. Phosphorylated Akt inactivates GSΚ-3β and inhibits apoptosis through phosphorylation of Bad and GSΚ-3β [56,57], indicating activation of the pathway. Isoflurane and mangiferin also raised the expression of p-mTORC1 and NF-κB, the downstream targets of Akt. NF-κB, is an important transcription factor that is associated with cell proliferation and cell cycle progression [58–60]. In our study we observed suppressed phosphorylation of Akt and GSΚ-3β with enhanced PTEN, the chief negative regulator of the pathway following ischemic insult [15], thus down-regulating PI3K/Akt signaling. Isoflurane and/or mangiferin-mediated enhanced expression of p-Akt and downstream molecules of Akt as – GSΚ-3β, nuclear factor-κB (NF-κB) and mTORC1. Increased expressions of mTORC2 indicates effective activation of Akt, leading to activation of the pathway. It is known that activated mTORC1 and mTORC2 eventually increase cell cycle progression and cell survival [15]. Further, the expression levels of phosphorylated forms of Akt, GSΚ-3β, mTORC1, and mTORC2 were more pronounced in animals that were exposed to isoflurane and treated with mangiferin compared to rats treated with isoflurane or mangiferin alone. Interestingly, anesthetic sevoflurane post-conditioning improved memory of neonatal rats following HI brain damage via activation of the PI3K/Akt signaling pathway [61]. The experimental data suggest that PI3K/Akt pathway activation is a potential mechanism involved in the protective effects of mangiferin and/or isoflurane. Furthermore, mangiferin significantly potentiated the neuroprotective effects of isoflurane via enhancing the PI3K/Akt pathway. These findings demonstrate mangiferin is a promising therapeutic agent in the treatment of neonatal ischemic brain injury, administered alone or with isoflurane.

**Conclusions**

The experimental data illustrate the neuroprotective effects of mangiferin and isoflurane in experimental neonatal HI and also show that administration of mangiferin clearly potentiated the protective effects of isoflurane. The molecular mechanisms underlying these protective effects warrant further study.

**Conflicts of interest**

None.
References:

1. Vannucci RC, Connor JR, Mauger DT et al: Rat model of perinatal hypoxic-ischemic brain damage. J Neurosci Res, 1999; 55: 158–63
2. Volpe JJ: Perinatal brain injury: From pathogenesis to neuroprotection. Ment Retard Dev Disabil Res Rev, 2001; 7: 56–64
3. Ferriero DM: Neonatal brain injury. N Engl J Med, 2004; 351: 1985–95
4. Sasaoka N, Kagawachi M, Kawai Y et al: Isoflurane exerts a short-term but not a long-term preconditioning effect in neonatal rats exposed to a hypoxic-ischaemic neuronal injury. Acta Anaesthesiol Scand, 2009; 53: 46–54
5. Ferriero DM, Bonifacio SL: The search continues for the elusive biomarkers of neonatal brain injury. J Pediatr, 2014; 164: 438–40
6. Verkman MT: The grieving details: Hypoxic-ischemic encephalopathy. J Perinat Neonat Nurs, 2009; 23: 59–68
7. Arteaga O, Revuelta M, Urigüen L et al: Pretreatment with resveratrol prevents neuronal injury and cognitive deficits induced by perinatal hypoxia–ischemia in rats. PloS One, 2015; 10: e0144224
8. Zhao P, Peng L, Li L et al: Isoflurane preconditioning improves long-term neurologic outcome after hypoxic ischemic brain injury in neonatal rats. Anesthesiology, 2007; 107: 963–70
9. Zhu W, Wang L, Zhang J: Isoflurane preconditioning neuroprotection in experimental focal stroke is androgen dependent in male mice. Neuroscience, 2010; 189: 758–69
10. Zhao P, Chai J, Long B: Protective effect of isoflurane postconditioning on reducing hypoxic-ischemic brain injury in neonatal rats. J China Med Univ, 2012; 41: 5–7
11. Zhao P, Yu W, Long B, Chai J: The neuroprotective effects of isoflurane on neonatal hypoxic–ischemic brain injury in the rats in various time points. Chin J Anesthesiol, 2012; 32: 979–81
12. Burchell SR, Dixon BJ, Tang J, Zhang JH: Isoflurane provides neuro-protection in neonatal hypoxic ischemic brain injury. J Invest Med, 2013; 61: 1078–83
13. Zitta K, Meybohm P, Bein B et al: Cytoprotective effects of the volatile anesthetic sevoflurane are highly dependent on timing and duration of sevo-flurane conditioning: Findings from a human, in-vitro hypoxia model. Eur J Pharmacol, 2010; 645: 39–46
14. Ye Z, Guo Q, Xia P et al: Sevoflurane post-conditioning involves an up-regulation of HIF-1alpha and HO-1 expression via PI3K/Akt pathway in a rat model of focal cerebral ischemia. Brain Res, 2012; 1463: 63–74
15. Zhang J, Yu XH, Yan YG et al: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta, 2015; 444: 182–92
16. Wang T, Gu J, Wu PF et al: Protection by tetrahydroxy sulfenylglucose against cerebral ischemia: Involvement of JNK, SIRT1, and NF-kappa B pathways and inhibition of intracellular ROS/RNS generation. Free Radic Biol Med, 2009; 47: 229–40
17. Chang W, Wei K, Ho L et al: A critical role for the mTORC2 pathway in lung fibrosis. PloS One, 2014; 9: e106155
18. Ferriero DM: Oxidant mechanisms in neonatal hypoxia-ischemia. Dev Neurosci, 2004; 26: 193–202
19. Buonocore G, Groenendaal F: Anti-oxidant strategies. Semin Fetal Neonatal Med, 2007; 12: 287–95
20. Warner DS, Sheng H, Batinic-Haberle I: Oxidants, antioxidants and the ischemic brain. J Exp Biol, 2004; 207: 3221–31
21. Arteaga O, Revuelta M, Montalvo H et al: Neuroprotective effect of antioxidants in neonatal rat brain after hypoxia–ischemia. In: Méndez-Vilas A (ed.), Microscopy: Advances in scientific research and educationm 2014; 335–43
22. Rocha-Ferreira E, Rudge B, Hughes MP et al: Immediate remote ischemic postconditioning reduces brain nitrotyrosine formation in a piglet asphyxia model. Oxid Med Cell Longev, 2016; 2016: 5763743
23. Tataranno ML, Perrone S, Longini M, Buonocore G: New antioxidant strategies for neonatal brain injury. Oxid Med Cell Longev, 2015; 2015: 108254
24. Tu XK, Yang WZ, Chen JP et al: Curcumin inhibits TRLR2/4-NF-κB signaling pathway and attenuates brain damage in permanent focal cerebral ischemia in rats. Inflammation, 2014; 37: 1544–51
25. Li Y, Qian Y, Fu L et al: Hydroxysoflavonoid yellow A exerts neuroprotective effects in cerebral ischemia-reperfusion-injured mice by suppressing the innate immune TLR4-induced pathway. Eur J Pharmocol, 2015; 769: 324–32
26. Qin J, Deng J, Feng X et al: Quantitative RP-LC analysis of mangiferin and homomangiferin in Mangifera indica L. leaves and in Mangifera persiciformis CYW and TL. mangifera leaf. Chromatographia, 2008; 68: 955–960
27. Sanchez GM, Re L, Giuliani A et al: Protective effects of Mangifera indica L. extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice. Pharmacol Res, 2000; 42: 565–73
28. Prabhu S, Jainu M, Sabitha KE et al: Role of mangiferin on biochemical alterations and antioxidants status in experimental myocardial infarction in rats. J Ethnopharmacol, 2006; 107: 126–33
29. Wang Q, Deng J, Yang K, Xu L: Effects of mangiferin on cytokines in rats with chronic bronchitis and expression of macrophage COX-2 in mice. Zhongguo Zhong Yao Za Zhi, 2011; 36: 1348–52
30. Garcia-Rivera D, Delgado R, Bougarne N et al: Gallic acid indanedione and mangiferin xanthone are strong determinants of immunosuppressive anti-tumour effects of Mangifera indica L. bark in MDAMB231 breast cancer cells. Cancer Lett, 2011; 305: 21–31
31. Dilshara MG, Kang CH, Choi YH, Kim GV: Mangiferin inhibits tumor necrosis factor-α-induced matrix metalloproteinase-9 expression and cellular invasion by suppressing nuclear factor-κB activity. BMB Rep, 2015; 48: 559–64
32. Li X, Cui X, Sun X et al: Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Phytother Res, 2010; 24: 893–99
33. Garber JC (Chair): Committee for the Update of the Guide for the Care and Use of Laboratory Animals. In: Guide for the Care and Use of Laboratory Animals. 8th ed. National Academy of Sciences, 2011
34. Zhao DA, Bi XJ, Huang Q et al: Isoflurane provides neuroprotection in neonatal hypoxic ischemic brain injury by suppressing apoptosis. Braz J Anesthesiol, 2016; 66: 613–21
35. You WC, Wang CX, Pan YX et al: Activation of nuclear factor-kappa B in the brain after experimental subarachnoid hemorrhage and its potential role in delayed brain injury. PloS One, 2010; 5: e11577
36. Bryce I, Boschi-Pinto C, Shibuya K, Black RE: WHO estimates of the causes of death in children. Lancet, 2005; 365: 1147–52
37. Cooper DJ: Induced hypothermia for neonatal hypoxic–ischemic encephalopathy: Pathophysiology, current treatment, and nursing considerations. Neonatal Netw, 2011; 30: 29–35
38. Zhao P, Zuo Z: Isoflurane preconditioning induces neuroprotection that is inducible nitric oxide synthase-dependent in neonatal rats. Anesthesiology, 2004; 101: 695–702
39. Chiari PC, Bienengeaerber MW, Pagel PS et al: Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: Evidence for anesthetic induced postconditioning in rabbits. Anesthesiology, 2005; 102: 102–9
40. Kim M, Kim M, Kim N et al: Isoflurane mitigates protection from renal ischemia–reperfusion injury via sphingosine kinase and sphingosine-1-phosphate-dependent pathways. Am J Physiol Heart Circ Physiol, 2007; 293: 1827–35
41. Zhao H, Yenari MA, Cheng D et al: Bcl-2 overexpression protects against neuron loss within the ischemic margin following experimental stroke and inhibits cytochrome c translocation and caspase-3 activity. J Neurochem, 2003; 85: 1026–36
42. Arteaga O, Alvarez A, Revuelta M et al: Role of antioxidants in neonatal hypoxic-ischemic brain injury: New therapeutic approaches. Int J Mol Sci, 2017; 18: E265
43. Wallin C, Puka-Sundvall M, Hagberg H et al: Alterations in glutatione and amino acid concentrations after hypoxia-ischemia in the immature rat brain. Brain Res Dev Brain Res, 2000; 125: 51–60
44. Zhao M, Zhu P, Fujino M et al: Oxidative stress in hypoxic-ischemic encephalopathy: Molecular mechanisms and therapeutic strategies. Int J Mol Sci, 2016; 17: E2078
45. Dai C, Liu Y, Dong Z: Tanshinone I alleviates motor and cognitive impairments via suppressing oxidative stress in the neonatal rats after hypoxic-ischemic brain damage. Mol Brain, 2017; 10: 52
46. Liang L, Ma Z, Dong M et al: Protective effects of salidroside against isoflurane-induced cognitive impairment in rats. Hum Exp Toxicol, 2017; 36: 1295–302

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
47. Wang D, Chen P, Chen L et al: Betulinic acid protects the neuronal damage in newborn rats from isoflurane-induced apoptosis in the developing brain by blocking FASL-FAS signaling pathway. Biomed Pharmacother, 2017; 95: 1631–35
48. Horwood JM, Dufour F, Laroche S, Davis S: Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci, 2006; 23: 3375–84
49. Aberg ND, Brywe KG, Isgaard J: Aspects of growth hormone and insulin like growth factor-I related to neuroprotection regeneration and functional plasticity in the adult brain. ScientificWorldJournal, 2008; 6: 53–80
50. Chiang HC, Wang L, Xie Z et al: PI3 kinase signaling is involved in Ab-induced memory loss in Drosophila. Proc Natl Acad Sci USA, 2010; 107(15): 7060–65
51. Xiong T, Tang J, Zhao J et al: Involvement of the Akt/GSK-3β/CRMP-2 pathway in axonal injury after hypoxia-ischemic brain damage in neonatal rat. Neuroscience, 2012; 216: 123–32
52. Li X, Zhang J, Chai S, Wang X: Progesterone alleviates hypoxic-ischemic brain injury via the Akt/GSK-3β signaling pathway. Exp Ther Med, 2014; 8: 1241–46
53. Yang Y, Zhang X, Cui H et al: Apelin-13 protects the brain against ischemia/reperfusion injury through activating PI3K/Akt and ERK1/2 signaling pathways. Neurosci Lett, 2014; 568: 44–49
54. Gu Q, Zhai L, Feng X et al: Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int, 2013; 63: 535–40
55. Tu X, Zhang HB, Shi SS et al: S-LOX inhibitor zileuton reduces inflammatory reaction and ischemic brain damage through the activation of PI3K/Akt signaling pathway. Neurochem Res, 2016; 41: 2779–87
56. Luo HR, Hatton H, Hossain MA et al: Akt as a mediator of cell death. Proc Natl Acad Sci USA, 2003; 100: 11712–17
57. Song G, Ouyang G, Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med, 2005; 9: 59–71
58. Kotliarova S, Pastorino S, Kovell LC et al: Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC nuclear factor-kappa B, and glucose regulation. Cancer Res, 2008; 68: 6643–51
59. Hayden MS, Ghosh S: NF-kappa B the first quarter-century: Remarkable progress and outstanding questions. Genes Dev, 2012; 26: 203–34
60. Perkins ND: The diverse and complex roles of NF-kappa B subunits in cancer. Nat Rev Cancer, 2012; 12: 121–32
61. Lai Z, Zhang L, Su J et al: Sevoflurane postconditioning improves long-term learning and memory of neonatal hypoxia-ischemia brain damage rats via the PI3K/Akt-mPTP pathway. Brain Res, 2016; 1630: 25–37